Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression ≥ 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexity. - Cortellini, Alessio; Garbo, Edoardo; La Cava, Giulia; Citarella, Fabrizio; Santo, Valentina; Brunetti, Leonardo; Pinato, David J; Naidoo, Jarushka; Loza, Monica; Genova, Carlo; Gettinger, Scott; Kim, So Yeon; et al. (Lung Cancer (01695002), 2025)